Clinical Trials | October 27, 2021
Dr Lal PathLabs to acquire Suburban Diagnostics for Rs 925 crore
Dr Lal PathLabs revenue contribution from west India to go up from 10% to 24% post-acquisition basis FY21
Dr Lal PathLabs revenue contribution from west India to go up from 10% to 24% post-acquisition basis FY21
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
The platform has seen an overall growth of 84% in the number of people seeking consultations for skin-related issues
Invisible Nation is a worldwide network of patient organizations committed to driving a decline in cardiovascular (CV) death by effecting systemic change in atherosclerotic cardiovascular disease (ASCVD) care
Express Scripts, a leading pharmacy benefit management organization, will list Viatris labelled biosimilar insulin Glargine as a preferred insulin brand on its National Preferred Formulary (NPF)
By combining Innovaccer's Data Activation Platform with HCL's robust healthcare data accelerator (hDATA) suite, organizations can enable patient-centricity, cost-optimization and compliance
The new products include the COAG Line automated, semi-automated and POC systems manufactured by Diagon Hungary
U.S. FDA to decide whether to authorize a booster dose in the coming days
This is a virtual event and the theme is `Transforming Healthcare beyond Covid’
In Western Europe, about 2% of procedures are done robotically while the majority, approximately 65%, are open surgery
Subscribe To Our Newsletter & Stay Updated
